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Abstract
Background:  This study was designed to assess the capability of ovarian reserve markers,
including baseline FSH levels, baseline anti-Müllerian hormone (AMH) levels, and antral follicle
count (AFC), as predictors of live births during IVF cycles, especially for infertile couples with
advanced maternal age and/or male factors.
Methods: A prospective cohort of 336 first IVF/ICSI cycles undergoing a long protocol with GnRH
agonist was investigated. Patients with endocrine disorders or unilateral ovaries were excluded.
Results: Among the ovarian reserve tests, AMH and age had a greater area under the receiving
operating characteristic curve than FSH in predicting live births. Furthermore, AMH and age were
the sole predictive factors of live births for women greater than or equal to 35 years of age; while
AMH was the major determinant of live births for infertile couples with absence of male factors by
multivariate logistic regression analysis. However, all the studied ovarain reserve tests were not
preditive of live births for women < 35 years of age or infertile couples with male factors.
Conclusion: The serum AMH levels were prognostic for pregnancy outcome for infertile couples
with advanced female age or absence of male factors. The predictive capability of ovarian reserve
tests is clearly influenced by the etiology of infertility.
Background
Adequate follicular development of ovaries in response to
gonadotropins has been referred to as ovarian reserve. The
primary value of ovarian reserve markers is to provide
assistance in selecting an appropriate protocol and/or ini-
tial dose of gonadotropins for controlled ovarian stimula-
tion (COS) in IVF cycles. In addition to being makers for
the ovarian response, an efficient indicator of pregnancy
outcome prior to COS would be of enormous help during
counseling, especially for expensive treatments, such as
IVF and ICSI. As a result, markers for ovarian reserve or
ovarian aging prior to COS are frequently utilized to pre-
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dict the pregnancy outcome of IVF/ICSI cycles [1,2]. How-
ever, the biomarkers for ovarian reserve or ovarian aging
prior to COS do not appear to predict pregnancy outcome
efficiently [1,2].
Currently, the clinically used ovarian reserve markers
include biochemical and sonographic markers. The serum
FSH levels [3,4] and/or antral follicular counts (AFC) [5-
7] in the early follicular phase represent the most com-
mon utilized biochemical and ultrasound markers for
ovarian aging in clinical practice, respectively. Anti-Mülle-
rian hormone (AMH), also referred to as Müllerian-inhib-
iting substance (MIS), is a member of the transforming
growth factor β superfamily [8]. The granulosa cells
within the preantral and small antral follicles in the ova-
ries are the sole source of AMH in rats [9] and humans
[10]. The baseline serum AMH levels have a better capa-
bility in predicting the ovarian response to COS than
other markers of ovarian reserve [11,12]. Indeed, the pre-
dictive value of AMH on pregnancy outcome has recently
attracted the attention of clinicians. However, conflicting
results regarding the correlation between the serum AMH
level and pregnancy outcome have been reported in the
literature [13-17].
The associated clinical factors for successful treatment of
IVF/ICSI have been studied extensively [18-20]. The major
clinical factors related to pregnancy outcome in IVF cycles
include the following: age of the patient [18], embryo
morphology [19], cause of infertility, and number of
embryos transferred [20]. Among these factors, the age of
the patients and the cause of infertility, together with the
ovarian reserve markers, are available prior to COS in the
general practice of IVF treatment.
The age of patients and the cause of infertility, however,
are not independent factors regarding patients undergo-
ing IVF/ICSI treatment. It has been reported that the prev-
alence of unexplained infertility increases in female
patients of advanced age (> 35 years) seeking infertility
treatment [21,22]. A putative cause of such unexplained
infertility was attributed to diminished ovarian reserve.
Nonetheless, the relationship between age and declining
reproductive capacity is highly variable [23]. These data
suggested that poor ovarian reserve may contribute to a
significant proportion of unexplained infertility, espe-
cially for patients > 35 years of age. The ovarian reserve
markers would probably connect with the outcome of
pregnancy for such patients.
The ovarian reserve markers feature the reproductive func-
tion of the female partner of infertile couples without tak-
ing into consideration the effect of the male partner. Thus,
the paternal effect is not evaluated by ovarian aging mark-
ers. Therefore, these markers may be more useful for cou-
ples with exclusive female factor infertility than couples
with male infertility. Recently, van Rooij [24] reported
that ovarian reserve tests are of limited value for predict-
ing ongoing pregnancy in patients with mild male infertil-
ity and unexplained infertility. Their study further raises
the possibility of an interaction between the etiology of
infertility and the ovarian reserve tests regarding preg-
nancy outcome.
Herein we propose that the efficiency of ovarian reserve
markers to predict pregnancy outcome may be better for
advanced age women and infertile couples with exclusive
female infertility. It would be helpful in clinical practice to
clarify the effectiveness of ovarian reserve markers for spe-
cific subpopulations of patients seeking IVF/ICSI treat-
ment. Therefore, we designed this study to compare the
predictive power of various markers of ovarian reserve for
the outcome of IVF/ICSI cycles using receiver operating
curve (ROC) analysis.
Furthermore, the paternal effect is generally exhibited sub-
sequent to fertilization. Embryo-related parameters may
become dominant for predicting live births for infertile
couples with male factor infertility. Consequently,
embryo markers together with ovarian reserve markers
and other clinical factors could be analyzed in a multivar-
iable logistic regression model.
Methods
Patient selection and stimulation protocols
The initial survey for etiology of infertility included the
following: computer-assisted semen analysis, hysterosalp-
ingography or laparoscopy for tubal patency, and serum
hormone levels of prolactin, estradiol, testosterone, FSH,
LH, and TSH. All IVF/ICSI cycles performed at the Lee
Women's Hospital in Taichung, Taiwan between March
2007 and December 2007 were enrolled. The patients
with the following characteristics were included for anal-
ysis: a long protocol for the use of a GnRH agonist, first
stimulation cycle for IVF/ICSI, the presence of bilateral
ovaries, and the absence of endocrine disorders, such as
polycystic ovarian syndrome or hyperprolactinemia. As a
result, 336 IVF/ICSI procedures were analyzed for this
study. The study protocol was approved by the Institu-
tional Review Board of Chung-Shan Medical University
Hospital. Consents were obtained from all the studied
participants.
The presence of male infertility was determined according
to the World Health Organization guidelines in 1999.
Specifically, the semen analysis revealed results of normal
(sperm concentration > 20×106/ml, percentage of motile
sperm > 50%, and normal sperm morphology ≥ 14%) for
at least two of three separate repeat tests at the time of ini-Reproductive Biology and Endocrinology 2009, 7:100 http://www.rbej.com/content/7/1/100
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tial sperm evaluation, sperm storage, and the day of
oocyte retrieval.
The women participating in this study followed a long
protocol for the use of a GnRH agonist as that described
in our previous report [25]. In brief, the protocol began
with daily subcutaneous injections of 0.5 mg leuprolide
acetate (LA Lupron; Takeda Pharmaceutics, Stolberg, Ger-
many) on day 21 of the pre-stimulation cycle. Gonado-
trophin (Gonal-F; Serono, Bari, Italy), at a dose of 225 IU/
day subcutaneously, was administered for cycle days 3 -7
and then the dose was adjusted according to the ovarian
response. The resulting ovarian response was monitored
by transvaginal ultrasound and serum estradiol levels.
When two or more follicles reached a maximum diameter
of 18 mm, 250 μg of hCG (Ovitrelle; Serono) was admin-
istered. Transvaginal oocyte retrieval was performed 32-
34 hours subsequent to hCG injection. Embryo transfer
was performed three days after oocyte retrieval.
Serum hCG was checked 14 days subsequent to embryo
transfer and patients with a level > 50 IU/L were consid-
ered pregnant. An ultrasound examination was preformed
one week later and then again three weeks later in order to
determine the number of intrauterine gestational sacs
present and fetal viability, respectively. The visible fetal
heart beat within theuterus by ultrasound constituted the
definition of a clinical pregnancy. All the pregnant
women subsequent to IVF/ICSI treatment were followed
until the termination of pregnancy or live birth. A living
child one week after delivery is defined as a live birth [26].
Monitoring ovarian response and hormone assay
Baseline hormone profiles, including serum levels of
estradiol, FSH, LH, and AMH were determined on day 3
of the pre-stimulation cycle. The AFC measurements were
performed by the same technician on days 3-5 of the men-
strual cycle. Antral follicles within the bilateral ovaries
between two and ten mm in diameter were recorded. A
7.5 MHz transvaginal probe was utilized for all examina-
tions. The ovarian response for all participants was moni-
tored using transvaginal ultrasound from day 7 of the
stimulation cycle and then continued at an interval of two
days until the day of hCG administration.
Serum FSH and LH were measured using a specific immu-
nometric assay kit (Immulite; Diagnostic Products Corpo-
ration, Los Angeles, CA, USA). The minimal detection
limit for FSH was 0.1 IU/L and the intra- and inter-assay
CVs for the FSH assay were 6.6% and 7.8%, respectively.
The detection limit and intra- and inter-assay CVs for the
LH assay were 0.1 IU/L and 6.5/7.1%, respectively. Estra-
diol and progesterone were also measured by competitive
immunoassay using the Immulite kit, and the intra- and
inter-assay CVs were 6.3% and 6.4% for estradiol and
6.3% and 5.8% for progesterone, respectively. The kit's
minimal detection limits for estradiol was 15 pg/ml and
0.2 ng/ml for progesterone.
Measurement of serum AMH levels was performed using
the AMH/MIS ELISA kit (Diagnostic Systems Lab, Web-
ster, TX, USA). The minimal detection limit and intra- and
inter-assay CVs for the AMH assay were 0.017 ng/ml and
< 5% and < 8%, respectively.
Classification of embryo quality
The embryos were classified according to the criteria pro-
posed by Steer [27], as follows: grade 1, equally-sized blas-
tomeres with no fragmentation; grade 2, equally- or
unequally-sized blastomeres with < 20% overall fragmen-
tation; grade 3, equally- orunequally-sized blastomeres
with 20%-50% fragmentation; and grade 4, equally- or
unequally-sized blastomeres with > 50% fragmentation.
The embryos with < 20% overall fragmentation (grade 1
or 2), together with > 6 blastomeres on day 3 were consid-
ered as good embryos [28].
A previous report from our cooperative group suggested
that transferring four embryos at the cleavage state would
obtain the maximal pregnancy rate in IVF treatment [29].
In Taiwan, the IVF/ICSI treatment is not covered by health
insurance; the financial burden has thus forced patients
and clinicians to make an agreement for transferring a
greater number of embryos. Therefore, the average
number of transferred embryos would be approximately
four to achieve a maximal pregnancy rate, even for the
young age group, in this study. If there were ≤ 4 embryos
available at the cleavage stage, then all embryos were
transferred into the uterus.
Statistical analysis
The various biologic parameters germane to IVF/ICSI
cycles of the data were analyzed by the chi-square test or
independent Student's t-test, as determined by respective
conditions. The age strata utilized by the Centers for Dis-
ease Control and Prevention and the Society for Assisted
Reproductive Technology for female age is as follows: < 35
years, 35 to < 38 years, 38 to < 40 years, and ≥ 40 years
(Centers for Disease Control and Prevention, 2007). We
attempted to identify the age groups adequate for clinical
application of ovarian reserve markers; therefore, the
youngest strata criterion (35 years) was utilized in this
study.
ROC curve analysis was used to estimate the predictive
power of the measured variables for pregnancy outcome.
The relative ability of ovarian reserve tests to predict the
IVF outcome were compared by calculating the areas
under the ROC curve (ROCAUC) and the 95% confidence
intervals (95% CIs). MedCalc software, version 9.3, wasReproductive Biology and Endocrinology 2009, 7:100 http://www.rbej.com/content/7/1/100
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used to compare the areas under two ROC curves (Med-
Calc, Broekstraat, Belgium).
Since ovarian reserve markers only exhibit moderate pre-
dictive power for live births in IVF/ICSI cycles [1], addi-
tional parameters might be helpful in establishing a
regression model for predicting outcome. In the literature,
several parameters have been reported to be related to
pregnancy outcome, such as etiology of infertility, dura-
tion of infertility, body mass index, the number of good
embryos (NGE), and the number of transferred embryos
(NET) [20]. A multivariate conditional logistical regres-
sion analysis was utilized with forward stepwise selection
procedures. The selection of variables was based on a P-
value < 0.2 to avoid erroneously excluding any prognostic
factors [30]. A confidence level of P < 0.05 was considered
to constitute the limit of statistical significance for com-
parison purposes. All the logistic regression analyses were
performed by the Statistical Package for the Social Sci-
ences, version 14.0 (SPSS Inc., Chicago, IL, USA).
Results
Between March 2007 and December 2007, a total of 336
IVF/ICSI cycles were recruited for this analysis. We ini-
tially divided the patients into two groups by age (i.e., <
35 years and ≥ 35 years) and then calculated the difference
for the biomarkers of ovarian reserve and etiology of infer-
tility, as shown in Table 1. All the biomarkers of ovarian
reserve surveyed (FSH, AFC, and AMH) showed a highly
significant difference between young and advanced age
patients (P < 0.001). The etiology of infertility also had
significant differences between the young and advanced
age groups of patients. The percentage of female factors
unrelated to tubal factor increased (14.6% vs. 28.5%),
whereas the incidence of male factors decreased (52.4%
vs. 32.5%) for patients ≥ 35 years of age compared to the
patients < 35 years of age (Table 1).
The outcome of IVF/ICSI cycles (i.e., the number of
retrieved oocytes, the pregnancy rates, and the live birth
rates) were all relevant to the chronologic age of the
patients (P < 0.05, Table 2). In addition, the patients ≥ 35
years of age had higher doses of exogenous gonado-
trophins, lower estradiol levels on the day of hCG admin-
istration, and a lower number of good embryos compared
to the patients < 35 years of age. Unfortunately, the
patients ≥ 35 years of age were characterized by a higher
incidence of no embryos available for transfer than the
patients < 35 years of age (5.8% vs. 0.5%, p = 0.004, Table
2). Furthermore, the implantation and live birth rates
were lower for patients ≥ 35 years of age compared to
those < 35 years of age (19.2% vs. 26.1%, p = 0.008 for
implantation rate; 32.5% vs. 43.7%, p = 0.044 for live
birth rate, Table 2).
The number of retrieved oocytes was the primary outcome
of ovarian response to COS in IVF/ICSI cycles in this
study. We evaluated the prognostic value of those ovarian
reserve markers for the number of retrieved oocytes by the
Pearson correlation coefficient (r). Figure 1 demonstrates
the relationship between the number of retrieved oocytes
and the biomarkers of ovarian reserve. All the ovarian
reserve markers, including age, baseline FSH levels, base-
line AMH levels, and AFC (r = -0.382, -0.359, 0.617, and
0.556, respectively, all P < 0.001, Figure 1) were closely
correlated with the number of retrieved oocytes. The AMH
and AFC exhibited a better correlation than age and FSH
for predicting the number of oocytes retrieved (P < 0.05).
Twelve patients (four due to no oocytes retrieved and
eight due to no embryos available for transfer) did not
undergo embryo transfer in this study. These cases were
excluded fromthe following ROC curve and multi-variant
logistic regression analyses. In addition, the values of
ovarian markers did not have a normal distribution and
the log transformation was performed for age, FSH, AFC,
and AMH.
The area under the corresponding ROC curves (ROCAUC)
for those markers were compared for the live births subse-
quent to IVF/ICSI cycles with at least one embryo trans-
ferred (Table 3). The levels of all ovarian reserve markers
did not predict the pregnancy outcome at a significant
level for patients < 35 years of age since the 95% CIs of
ROCAUC for the corresponding curves include 0.5 (Table
3), while for women ≥ 35 years of age the levels of AMH
and female age demonstrated significantly better predict-
ing capability than FSH (p < 0.05, Table 3).
Table 1: Demographic data regarding the patients (n = 336) 
participating in IVF/ICSI treatment of different age groups.
Age < 35
(n = 213)
Age ≥ 35
(n = 123)
P value
Chronologic age (years) 30.8 ± 0.2 38.6 ± 0.2 < 0.001a
Baseline FSH level (IU/L) 7.60 ± 0.26 9.63 ± 0.47 < 0.001a
Antral follicle count 7.8 ± 0.3 4.2 ± 0.3 < 0.001a
Baseline AMH level (ng/ml) 2.73 ± 0.13 1.85 ± 0.15 < 0.001a
Duration of infertility (years) 3.2 ± 0.2 4.7 ± 0.3 < 0.001a
Body mass index (kg/m2) 21.4 ± 0.2 22.0 ± 0.3 0.086a
Etiology of infertility
Tubal factor 31 (14.6%) 22 (17.9%) 0.519b
Other female factor 31 (14.6%) 35 (28.5%) 0.003b
Male factor 111 (52.4%) 40 (32.5%) < 0.001b
Mixed 34 (16.0%) 24 (19.5%) 0.504b
Unexplained 6 (2.8%) 2 (1.6%) 0.922c
The data are presented as the mean ± SD or percentage.
a. Comparison of the two groups by Student's t-test
b. Comparison by X2 test
c. Comparison by Fischer's exact testReproductive Biology and Endocrinology 2009, 7:100 http://www.rbej.com/content/7/1/100
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We further separately analyzed the significance of those
ovarian reserve markers in predicting pregnancy outcome
for couples with and without male factors (Table 3). The
individual ROCAUC of the corresponding ovarian aging
markers had no predictive power for infertile couples with
the presence of male factors. Nonetheless, the levels of
FSH, AFC, and AMH, but not female age, exhibited the
capability of predicting live births for infertile couples
without male factors (Table 3).
By a multivariate logistic regression analysis, we found
that the number of good embryos (NGE) was the sole
important predictor for pregnancy outcome in IVF cycles
(odds ratio: 1.319, p < 0.05, Table 4) for women < 35
years of age; however, the ovarian reserve markers were
not significant predictors for patients of this subgroup. In
contrast, for women ≥ 35 years of age, the logAMH and
logAge were the sole significant predictors of pregnancy
outcome in IVF cycles (odds ratio: 2.013 and 0.001,
respectively, p < 0.05, Table 4). The embryo-related
parameters were not as effective as ovarian reserve mark-
ers to predict pregnancy outcome for women ≥ 35 years of
age.
Interestingly, the logAMH was the sole factor to predict live
birth (odds ratio: 2.120, p < 0.05) for infertile couples
without male factors subsequent to the logistic regression
analysis (Table 4). The NGE was the major predictors of
pregnancy and live births for infertile couples with male
factors (odds ratio: 1.322, p < 0.05; Table 4).
The ROC curve analysis demonstrated that the AMH was
able to predict live births in IVF cycles for women ≥ 35
years of age. The cut-off point indicated by the ROC curve
for women ≥ 35 years of age was at a level of 1.68 ng/ml.
The sensitivity was 60.0%, the specificity was 66.2%, the
positive predictive value was 49.0%, and the negative pre-
dictive value was 75.4%.
The baseline AMH values are not normally distributed, as
described in previous reports [31,32], therefore the
patients were classified into four subgroups according to
the 25th, 50th, and 75th percentile levels of serum AMH lev-
els (1.08 ng/ml, 1.97 ng/ml, and 3.26 ng/ml, respectively)
in order to clarify the predictive value of AMH for ovarian
response and pregnancy outcome (Figure 2). The AMH
levels were significantly correlated with the response to
the number of retrieved oocytes and the number of cul-
tured good embryos (Figures 2A and 2B). However, the
AMH level was not significantly associated with the
implantation rate (Figure 2C). The pregnancy and live
birth rates for the patients in the lowest quartile group
were significantly lower than the other three groups (Fig-
ures 2D and 2E).
Discussion
In the present study, all the surveyed ovarian reserve
markers, including baseline FSH levels, baseline AMH lev-
els, and AFC, were significantly relevant to the chrono-
logic age of the female partner of infertile couples (Table
1). Furthermore, all the ovarian reserve markers, includ-
ing age, were intimately correlated with the number of
oocytes retrieved (Figure 1). Specifically, AMH levels and
AFC exhibited more prognostic value than age and FSH
levels for ovarian reserve, i.e., the number of retrieved
oocytes according to the 95% CI of the corresponding
Pearson correlation coefficient. The results are concordant
with previous reports [11,15]. Both the serum hormone
levels (AMH) and ultrasound criteria (AFC) could be uti-
lized for assessment of ovarian reserve at a similar level of
significance.
Table 2: Outcome data regarding the patients (n = 336) participating in IVF/ICSI treatment of different age groups.
Age < 35
(n = 213)
Age ≥ 35
(n = 123)
P value
Gonadotropin dose (IU) 1958 ± 23 2153 ± 45 < 0.001 a
Estradiol levels on the day of hCG administration (pg/ml) 1976 ± 85 1391 ± 92 < 0.001a
Number of retrieved oocytes 12.3 ± 0.5 8.3 ± 0.5 < 0.001a
Number of transferred embryos 3.9 ± 0.1 3.1 ± 0.2 < 0.001a
Number of good embryos 3.2 ± 0.1 2.2 ± 0.2 < 0.001a
Cycle number with no oocytes retrieved 2/213 (0.9%) 2/123 (1.6%) 0.626b
Cycle number with no embryos transferred 1/211 (0.5%) 7/121 (5.8%) 0.004b
Pregnancy rate (%) 112/213 (52.6) 48/123 (39.0) 0.022c
Implantation rate (%) 217/830 (26.1) 74/386 (19.2) 0.008c
Multiple pregnancy rate (%) 64/112 (57.1) 20/48 (41.7) 0.106c
Live birth rate (%) 93/213 (43.7) 40/123 (32.5) 0.044c
The data are presented as the mean ± SD or percentage.
a. Comparison of the two groups by Student's t-test
b. Comparison by Fisher's exact test
c. Comparison by X2 testReproductive Biology and Endocrinology 2009, 7:100 http://www.rbej.com/content/7/1/100
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The etiology of infertility is not independent from the age
of the female patient, as demonstrated in Table 1. During
the years prior to the menopause, oocytes in the human
ovaries undergo an accelerated rate of loss until the cohort
of oocytes is nearly depleted. It has been reported that this
accelerated loss is initiated when the total number of
oocytes reaches approximately 25,000, a number or
threshold reached in normal women at an age of 37-38
years [33,34]. If the female partner of infertile couples
exceeds the age of 38 years, the etiology of infertility
would be classified as female age factor instead of unex-
plained infertility in our infertility clinic. Since endocrine
disorders of female partners were excluded in the present
study, the couples with feamle age factor (former unex-
plained infertility) contributed a significant proportion of
other female factors for patients ≥ 35 years of age.
To predict pregnancy outcome or live birth by ovarian
reserve markers is a relative complicated process. Based
upon the results of this study, we identified that the stud-
ied ovarian reserve markers exhibited a predictive capabil-
ity for live births only in some specific subgroups of
infertile couples, such as those with advanced female age
and/or absence of male factor infertility (Table 3). Among
the ovarian reserve makers surveyed in this study, female
age and AMH demonstrated better predictive power for
live births than FSH for women ≥ 35 years of age (Table
3). The results revealed in Table 3 are compatible with our
hypothesis that the prognostic value of ovarian reserve
markers for live births was greater for women of advanced
age than that for young aged women.
The ovarian reserve markers targeted the evaluation of
ovarian function for the female partner of infertile cou-
ples. Therefore, we further suggest that these markers were
more important for infertile couples with exclusive female
factors than those couples with male factors. Table 3 dem-
onstrated that AMH, AFC, and FSH were able to predict
pregnancy outcome of IVF cycles for infertile couples
without male factors. In addition, the ROCAUC for AMH
featured the greatest area among these biomarkers,
although the difference did not reach statistical signifi-
cance. Interestingly, none of these biomarkers was able to
predict the live births after ART cycles for couples with
male factor infertility.
Several parameters obtained during the process of the
infertility work-up have been reported to be relevant to
the pregnancy outcome for IVF cycles, such as the etiology
of infertility, body mass index, and the duration of infer-
tility [20]. Furthermore, embryo morphology and number
of transferred embryos are viewed as important predictors
of pregnancy outcome in IVF cycles [19,35]. As a conse-
quence, these parameters were added in the analysis of the
logistic regression model for pregnancy outcome of IVF/
The correlation between ovarian reserve markers and the  number of retrieved oocytes Figure 1
The correlation between ovarian reserve markers 
and the number of retrieved oocytes. A. chronologic 
age, B. basal FSH levels, C. basal AMH levels, D. antral follicle 
count. The Pearson correlation coefficient (r) was presented 
as the value (95% confidence interval, P value).Reproductive Biology and Endocrinology 2009, 7:100 http://www.rbej.com/content/7/1/100
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ICSI cycles. The multivariate logistic regression model fur-
ther confirmed that number of good embryos (an
embryo-related parameter) was the major predictor for
women < 35 years of age and/or infertile couples with
male factors. By contrast, AMH (an ovarian aging marker)
was more prognostic than embryo-related parameters for
women ≥ 35 years of age or infertile couples without male
factors (Table 4).
A high multiple pregnancy rates were observed accompa-
nied with the embryo transfer policy in this study (Table
2). The different policy for embryo transfer in this study
and other reports provide at least a partial explanation
about the conflicting results in the literature for AMH in
predicting pregnancy outcome [13-17]. If the policy
regarding embryo transfer changes, the significance of
ovarian reserve markers might change as well.
First, when the maximal number of transferred embryos is
limited to two, as reported by Smeenk et al. [16] and
Lekamge et al. [17], the ovarian reserve markers would
have less of an influence on the number of good quality
embryos destined to be transferred. Figure 2 shows that
the AMH level in the lowest quartile was associated with a
limited number of good embryos and a poor pregnancy
outcome. The results suggested that the number of good
embryos might be influenced by the levels of AMH, espe-
cially for patients with poor ovarian reserve, when the
upper limit for the number of transferred embryos was
three or more [13,15]. But in the case of an embryo trans-
fer number limited to two, most patients would have suf-
ficient good embryos for transfer. Therefore, the influence
of AMH (ovarian reserve marker) would decrease in such
a situation.
Second, the number of good embryos was higher in
patients with higher AMH levels for all study-recruited
women (Figure 1). Thereafter, those cycles with high AMH
levels would have more embryos for cryopreservation and
would result in high cumulative pregnancy rates. It has
been reported that for women ≤ 38 years of age with a
basal FSH < 10 IU/L, the AMHlevels is positively corre-
lated with the cumulative pregnancy outcome [17]. They
also reported that the clinical pregnancy rates per transfer
in fresh cycles were not different between high and low
AMH groups [17].
Table 3: Comparison of areas under the ROC curves of predictors (ovarian reserve markers) to live births.
Ovarian reserve 
markers
Age < 35
(n = 210)
Age ≥ 35
(n = 114)
Male factor presence
(n = 203)
Male factor absence
(n = 121)
Total
(n = 324)
logFSH 0.517(0.441~0.593) 0.531(0.448~0.613)ab 0.527(0.456~0.597) 0.603(0.510~0.690) 0.524(0.468~0.579)
log(AFC+1) 0.573(0.496~0.647) 0.583(0.499~0.663) 0.571(0.478~0.660) 0.574(0.503~0.643) 0.572(0.517~0.627)
logAMH 0.511(0.435~0.587) 0.653(0.571~0.729)a 0.539(0.468~0.609) 0.654(0.562~0.738) 0.577(0.521~0.631)
logAge 0.508(0.432~0.584) 0.656(0.574~0.732)b 0.539(0.468~0.609) 0.572(0.479~0.662) 0.549(0.493~0.604)
The patients were divided into different groups by age (35 years) and the presence of male factor infertility. The data were presented as the area 
under the curve and the 95% confidence interval.
a: p = 0.035, b: p = 0.050, by comparison of the area under the corresponding ROC curve
Table 4: Odds ratio subsequent to conditional logistic regression model based on the surveyed ovarian reserve markers and 
pregnancy-related parameters.
Variables Age < 35
(n = 210)
Age ≥ 35
(n = 114)
Male factor presence
(n = 203)
Male factor absence
(n = 121)
Total
(n = 324)
logAMH -- 2.055
(1.285~3.286)
-- 2.120
(1.308~3.436)
1.580
(1.197~2.086)
logAGE -- 0.001
(0.000~0.053)
-- -- --
NGE 1.319
(1.128~1.543)
-- 1.322
(1.094~1.598)
-- --
The factors for analysis included female age, duration of infertility, body mass index, logAMH, log AFC, log FSH, number of transferred embryos, 
and number of good embryos (NGE). The final prediction models were listed below the table. The significant coefficients were shown as the 95% 
confidence interval.
For patients < 35 years of age: Fertility index (live birth) = -0.633 + 0.277 × NGE
For patients ≥ 35 years of age Fertility index (live birth) = 34.256 + 0.700 × logAMH - 9.664 × logAGE
For couples with male factor: Fertility index (live birth) = -1.587 + 0.279 × NGE
For couples without male factor: Fertility index (live birth) = -0.637 + 0.751 × logAMH
For all the couples in this study: Fertility index (live birth) = -0.667+ 0.457 × logAMH
The probability (p) of live births can be calculated through p = eFertility index/(1+eFertility index)Reproductive Biology and Endocrinology 2009, 7:100 http://www.rbej.com/content/7/1/100
Page 8 of 10
(page number not for citation purposes)
Regarding the relationship between embryo quality and
AMH, controversial data exist in the literature [13,16]. In
this study, the basal AMH level was not correlated with the
implantation rate (Figure 1C). The results suggest that the
association of AMH levels with the number of good
embryos resulted from the fact that more oocytes were
retrieved in IVF cycles from the patients with higher AMH
levels. These results were similar to the finding reported
by Hazout et al. in 2004 [13] and Eldar-Geva et al. in 2005
[15].
The range of AMH levels in this study were similar to that
reported by Smeenk et al. [16], although the kit for AMH
measurement was not the same in our study. The kit for
AMH measurement was the same in those reports with
conflicting results about AMH and pregnancy [13-17].
Furthermore, a recent study reported that the two kits for
measuring AMH were closely correlated [36]. Therefore,
the difference in ELISA kits for AMH do not account for
the different results among the current study and those
reports. In addition, the distribution of quartile levels in
this study (1.08 ng/ml, 1.97 ng/ml, and 3.26 ng/ml) are
similar to a previous report (5.7 pmol/l, 9.3 pmol/l, 16.4
pmol/l [for AMH levels, pmol/l = ng/ml × 7.143]) [32].
The current study and the report by Nelson et al. in 2007
[32] utilized the same kit for AMH measurement, which
further supports the reproducibility of the AMH kit
applied in the current report.
Our previous report [35] and the current study have both
revealed that embryo-related parameters are not able to
predict pregnancy outcome compared to biomarkers of
ovarian reserve for women ≥ 35 years of age. The current
study further supports the concept that an ovarian reserve
evaluation is more important for women ≥ 35 years of age
or infertile couples with exclusive female factors. These
data will add greatly in counseling prior to COS, espe-
cially for women of advanced age or a relatively normal
male partner subsequent to semen analysis, as demon-
strated in Tables 3 and 4. The AMH levels might be uti-
lized efficiently to discriminate diminished ovarian
reserve for women ≥ 35 years of age, especially for couples
with unexplained infertility [21].
Conclusion
The ovarian reserve tests, especially AMH and AFC, are
well-correlated to the ovarian response. When the results
of ovarian reserve tests are utilized to predict the preg-
nancy outcome, the etiology of infertility and female age
should be taken into consideration. The results of ovarian
reserve tests, especially AMH, available prior to COS
allows the clinician to give couples, for whom the female
partner is ≥ 35 years of age or couples with exclusive
female factors, a more accurate estimation for their
chances of live births subsequent to IVF/ICSI treatment.
Comparison of the outcome of IVF cycles grouping by base- line levels of serum anti-Mullerian hormone (the 25th, 50th,  and 75th percentile levels are 1.08 ng/ml, 1.97 ng/ml, and 3.26  ng/ml, respectively) Figure 2
Comparison of the outcome of IVF cycles grouping 
by baseline levels of serum anti-Mullerian hormone 
(the 25th, 50th, and 75th percentile levels are 1.08 ng/
ml, 1.97 ng/ml, and 3.26 ng/ml, respectively). A. The 
number of retrieved oocytes, B. the number of cultured 
good embryos, C. implantation rates, D. the rates of clinical 
pregnancy, E. the live birth rate. a. p < 0.05 by one-way 
ANOVA and post-hoc Bonferroni test compared to all the 
other three groups. b. p < 0.05 by X2 test.Reproductive Biology and Endocrinology 2009, 7:100 http://www.rbej.com/content/7/1/100
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